

16.1.5 SIGNATURES INVESTIGATORS

**PRINCIPAL OR COORDINATING
INVESTIGATOR(S) SIGNATURE(S)
OR SPONSOR’S RESPONSIBLE MEDICAL OFFICER**

STUDY TITLE: APL2-308 (PRINCE)
A Phase 3, Randomized, Multicenter, Open-Label,
Controlled Study to Evaluate the Efficacy and Safety of
Pegcetacoplan in Patients with Paroxysmal Nocturnal
Hemoglobinuria (PNH)

STUDY AUTHOR(S): Apellis Pharmaceuticals, Inc.

I have read this report and confirm that to the best of my knowledge it accurately describes the
conduct and results of the study


INVESTIGATOR OR SPONSOR’S RESPONSIBLE MEDICAL OFFICER:

Dr. Raymond wong

The Chinese University of Hong Kong

Raymond wong

(Printed Name, Affiliation)


Signer Name: Dr. Raymond Wong
Signing Reason: I approve this document
Signing Time: 28-Oct-2021 | 11:01 EDT
404F72E852D34B3A85123F03AF453CF1

(Signature)

28-Oct-2021 | 11:01 EDT

(Date)